New insider activity at Becton Dickinson ( (BDX) ) has taken place on August 8, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Claire Fraser-Liggett recently sold 863 shares of Becton Dickinson stock, amounting to a total transaction value of $165,954.
Recent Updates on BDX stock
Becton, Dickinson and Co (BDX) announced the completion of a clinical study evaluating the PureWick™ System, a non-invasive urine management device, against an established comparator. The study, which focused on safety, efficacy, and user experience, could positively impact BDX’s stock performance by enhancing investor confidence in the product’s market viability. This development positions BDX favorably in the healthcare industry’s shift towards innovative non-invasive solutions.
Spark’s Take on BDX Stock
According to Spark, TipRanks’ AI Analyst, BDX is a Outperform.
Becton Dickinson’s overall stock score reflects its strong financial performance, strategic initiatives, and positive earnings outlook. The company’s robust revenue growth, improved margins, and strategic transactions position it well for future growth. However, valuation concerns and market challenges in China present potential risks. The technical indicators suggest short-term positive momentum, supporting the overall positive outlook.
To see Spark’s full report on BDX stock, click here.
More about Becton Dickinson
YTD Price Performance: -16.40%
Average Trading Volume: 2,965,119
Technical Sentiment Signal: Sell
Current Market Cap: $49.41B